-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Dyne Therapeutics (NASDAQ:DYN) Given New $23.00 Price Target at Piper Sandler
Dyne Therapeutics (NASDAQ:DYN) Given New $23.00 Price Target at Piper Sandler
Dyne Therapeutics (NASDAQ:DYN – Get Rating) had its price objective hoisted by Piper Sandler from $17.00 to $23.00 in a research report report published on Tuesday morning, The Fly reports.
DYN has been the subject of several other research reports. Raymond James began coverage on Dyne Therapeutics in a research note on Monday, July 11th. They issued an outperform rating and a $15.00 target price for the company. Chardan Capital began coverage on Dyne Therapeutics in a research note on Wednesday, July 20th. They issued a buy rating and a $17.00 target price for the company. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $21.00.
Get Dyne Therapeutics alerts:Dyne Therapeutics Stock Up 5.3 %
DYN stock opened at $11.67 on Tuesday. The firm has a market capitalization of $604.10 million, a PE ratio of -3.31 and a beta of 0.70. Dyne Therapeutics has a twelve month low of $4.30 and a twelve month high of $17.89. The stock has a 50-day simple moving average of $11.09 and a two-hundred day simple moving average of $8.03.
Dyne Therapeutics (NASDAQ:DYN – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.22). On average, equities research analysts anticipate that Dyne Therapeutics will post -3.59 EPS for the current fiscal year.Institutional Investors Weigh In On Dyne Therapeutics
A number of institutional investors have recently modified their holdings of DYN. PDT Partners LLC lifted its holdings in Dyne Therapeutics by 113.1% in the fourth quarter. PDT Partners LLC now owns 28,784 shares of the company's stock valued at $342,000 after acquiring an additional 15,275 shares during the period. GSA Capital Partners LLP raised its stake in shares of Dyne Therapeutics by 23.1% in the fourth quarter. GSA Capital Partners LLP now owns 23,193 shares of the company's stock worth $276,000 after buying an additional 4,357 shares during the period. Deep Track Capital LP bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $27,255,000. Summit Rock Advisors LP bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $415,000. Finally, Monashee Investment Management LLC raised its stake in shares of Dyne Therapeutics by 193.5% in the first quarter. Monashee Investment Management LLC now owns 279,704 shares of the company's stock worth $2,696,000 after buying an additional 184,404 shares during the period. 90.22% of the stock is owned by hedge funds and other institutional investors.
Dyne Therapeutics Company Profile
(Get Rating)
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Recommended Stories
- Get a free copy of the StockNews.com research report on Dyne Therapeutics (DYN)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
- Broadcom Bounces From Institutional Bottom
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Dyne Therapeutics (NASDAQ:DYN – Get Rating) had its price objective hoisted by Piper Sandler from $17.00 to $23.00 in a research report report published on Tuesday morning, The Fly reports.
據The Fly報道,在週二上午發佈的一份研究報告中,派珀·桑德勒將戴恩治療公司(納斯達克:DYN-GET評級)的價格目標從17.00美元上調至23.00美元。
DYN has been the subject of several other research reports. Raymond James began coverage on Dyne Therapeutics in a research note on Monday, July 11th. They issued an outperform rating and a $15.00 target price for the company. Chardan Capital began coverage on Dyne Therapeutics in a research note on Wednesday, July 20th. They issued a buy rating and a $17.00 target price for the company. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $21.00.
Dyn一直是其他幾份研究報告的主題。雷蒙德·詹姆斯於7月11日星期一在一份研究報告中開始報道戴恩治療公司。他們對該公司發佈了跑贏大盤的評級和15.00美元的目標價。Chardan Capital在7月20日星期三的一份研究報告中開始報道Dye治療公司。他們為該公司發佈了買入評級和17.00美元的目標價。一名股票研究分析師對該股的評級為賣出,四名分析師對該公司股票的評級為買入。根據MarketBeat的數據,該公司目前的共識評級為中等買入,平均目標價為21.00美元。
Dyne Therapeutics Stock Up 5.3 %
戴恩治療公司股票上漲5.3%
DYN stock opened at $11.67 on Tuesday. The firm has a market capitalization of $604.10 million, a PE ratio of -3.31 and a beta of 0.70. Dyne Therapeutics has a twelve month low of $4.30 and a twelve month high of $17.89. The stock has a 50-day simple moving average of $11.09 and a two-hundred day simple moving average of $8.03.
週二,Dyn的股價開盤報11.67美元。該公司市值為6.041億美元,市盈率為-3.31,貝塔係數為0.70。戴恩治療公司的12個月低點為4.30美元,12個月高位為17.89美元。該股的50日簡單移動均線切入位為11.09美元,200日簡單移動均線切入位為8.03美元。
Institutional Investors Weigh In On Dyne Therapeutics
機構投資者對戴恩治療公司的看法
A number of institutional investors have recently modified their holdings of DYN. PDT Partners LLC lifted its holdings in Dyne Therapeutics by 113.1% in the fourth quarter. PDT Partners LLC now owns 28,784 shares of the company's stock valued at $342,000 after acquiring an additional 15,275 shares during the period. GSA Capital Partners LLP raised its stake in shares of Dyne Therapeutics by 23.1% in the fourth quarter. GSA Capital Partners LLP now owns 23,193 shares of the company's stock worth $276,000 after buying an additional 4,357 shares during the period. Deep Track Capital LP bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $27,255,000. Summit Rock Advisors LP bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $415,000. Finally, Monashee Investment Management LLC raised its stake in shares of Dyne Therapeutics by 193.5% in the first quarter. Monashee Investment Management LLC now owns 279,704 shares of the company's stock worth $2,696,000 after buying an additional 184,404 shares during the period. 90.22% of the stock is owned by hedge funds and other institutional investors.
一些機構投資者最近調整了對Dyn的持股。PDT Partners LLC在第四季度增持了戴恩治療公司的股份113.1%。PDT Partners LLC現在擁有28,784股該公司的股票,價值342,000美元,在此期間又購買了15,275股。GSA Capital Partners LLP在第四季度將其在Dye Treateutics的股份增加了23.1%。GSA Capital Partners LLP現在擁有23,193股該公司股票,價值27.6萬美元,在此期間又購買了4,357股。Deep Track Capital LP在第四季度購買了戴恩治療公司的新股票頭寸,價值約27,255,000美元。Summit Rock Advisors LP在第四季度購買了戴恩治療公司的新頭寸,價值約415,000美元。最後,Monashee Investment Management LLC在第一季度將其在戴恩治療公司的股份增加了193.5%。Monashee Investment Management LLC現在擁有279,704股該公司股票,價值2,696,000美元,在此期間又購買了184,404股。90.22%的股票由對衝基金和其他機構投資者持有。
Dyne Therapeutics Company Profile
戴恩治療公司簡介
(Get Rating)
(獲取評級)
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
戴恩治療公司是一家肌肉疾病公司,作為一家生物技術公司,專注於在美國推進遺傳驅動的肌肉疾病的治療。它利用其提供疾病修正療法的FORCE平臺,為強直性肌營養不良1型、Duchenne肌營養不良和麪肩肩關節營養不良以及罕見的骨骼肌、心臟和代謝性肌肉疾病開發各種計劃。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Dyne Therapeutics (DYN)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
- Broadcom Bounces From Institutional Bottom
- 免費獲取StockNews.com關於戴恩治療公司(Dyn)的研究報告
- 3低貝塔防禦性股票為艱難的市場做準備
- 對於這三隻股票來説,這可能是一個值得記住的9月
- 在預訂增加的情況下,Roblox能否扭轉預訂量下降的局面
- 通脹峯值為布林克國際股票設定底部
- 博通從機構底部反彈
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《戴恩治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收對戴恩治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧